A phase II study of thalidomide in patients with brain metastases from malignant melanoma

Acta Oncologica

Volumn 47, Issue 8, 2008, Pages 1526-1530

  Vestermark, Lene W ^a   Larsen, Susanne ^a   Lindeløv, Birgit ^b   Bastholt, Lars ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b LILLEBAELT HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; THALIDOMIDE;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BRAIN METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE ESCALATION; FATIGUE; FEMALE; HUMAN; MALE; MELANOMA; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOMNOLENCE; SURVIVAL TIME; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 54449099006     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860801918521     Document Type: Article

References (25)

1. Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: Results of a meta-analysis. Melanoma Res 2000;10:81-92.
2. O'Day S, Atkins M, Weber J, Thompson J, Anderson C, Gonzalez R et al. A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM). ASCO 2005.
3. Meier S. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie 2004;27:145-9.
4. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000;12:573.
5. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 1994;91:4082-5.
6. Quilitz R, Pharm D. Thalidomide in oncology. The peril and the promise. Cancer Control, JMCC 1999;6:483-95.
7. Rajkumar SV. Thalidomide in the treatment of cell malignancies. J Clin Oncol 2001;19:3593-5.
8. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
9. Meierhofer C, Wiedermann CJ. New insights into the pharmacological and toxicological effects of thalidomide. Curr Opin Drug Discov Devel 2003;6:92-9.
10. Meierhofer C. Theoretical basis for the activity of thalidomide. BioDrugs 2001;15:681-703.
11. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802-11.
12. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Atitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 1999;341:1565-71.
13. Raje N, Anderson KC. Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 2002;14:635-40.
14. Eleutherakis-Papaiakovou V. Thalidomide in cancer medicine. Ann Oncol 2004;15:1151-60.
15. Richardson P. Thalidomide: Emerging role in cancer medicine. Annu Rev Med 2002;53:629-57.
16. Kumar S. Thalidomid: Current role in the treatment of nonplasma cell malignancies. 12 2005;22:2477-88.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
18. Zeldis J, Williams B, Thomas S, Elsayed M. S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21:319-30.
19. Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
20. Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res 2004;14:57-62.
21. Reiriz AB, Richter MF, Fernandes S, Cancela AI, Costa TD, DiLeone LP, et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res 2004;14:527-31.
22. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, et al. Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82:812-7.
23. Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: Current results and rationale for dosing/scheduling. Crit Rev Oncol/Hematol 2004;53:241-52.
24. Brock C, Newlands E, Wedge S, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7.
25. Tolcher A, Gerson S, Denis L, Geyer C, Hammond L, Patnaik A, et al. Marked inactivation of 06-alkylguanine-DNA alkyltransferase activity with protected temozolomide schedules. Br J Cancer 2003;88:1004-11.